Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.

G L DeNardo; S J DeNardo; D S Goldstein; L A Kroger; K R Lamborn; N B Levy; J P McGahan; Q Salako; S Shen; J P Lewis

doi:10.1200/JCO.1998.16.10.3246

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.

Identifier:nobleid.org/w1/20260515/B8BEAF95

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/B8BEAF95.svg?ark=w1%2F20260515%2FB8BEAF95)](https://nobleid.org/work/w1/20260515/B8BEAF95)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.

Identifier:nobleid.org/w1/20260515/B8BEAF95

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/B8BEAF95.svg?ark=w1%2F20260515%2FB8BEAF95)](https://nobleid.org/work/w1/20260515/B8BEAF95)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work